Phase 2
A new readout from a Phase IIb/III trial showed intravenous RLF-100 (aviptadil) met the primary endpoint of improving survival and recovery at 60 days post-treatment for respiratory failure in critically ill patients with COVID-19.
Orphazyme announced its Phase II/III clinical trial of arimoclomal for inclusion body myositis (IBM) failed to hit both its primary and secondary endpoints.
There was a fair amount of clinical trial news last week. Here’s a look.
With oncology drugs clocking a disheartening 3.4% success rate, some good news in the field is always appreciated.
The study involved observations in neurologic function, cognition and biomarkers in three repeated administrations of Nurown®, which were given two months apart.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
PRESS RELEASES